Lorundrostat

Lorundrostat
Clinical data
Other namesMLS 101
Legal status
Legal status
  • Investigational
Identifiers
  • N-(4-Acetamidocyclohexyl)-2-[4-[5-(4-methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-yl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H33N7O2
Molar mass451.575 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C2=CN=NC(=N2)N3CCN(CC3)CC(=O)NC4CCC(CC4)NC(=O)C
  • InChI=1S/C24H33N7O2/c1-17-3-5-19(6-4-17)22-15-25-29-24(28-22)31-13-11-30(12-14-31)16-23(33)27-21-9-7-20(8-10-21)26-18(2)32/h3-6,15,20-21H,7-14,16H2,1-2H3,(H,26,32)(H,27,33)
  • Key:YHGVDZULVMINCJ-UHFFFAOYSA-N

Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants.[1][2][3][4]

References

  1. ^ Laffin, Luke J.; Rodman, David; Luther, James M.; Vaidya, Anand; Weir, Matthew R.; Rajicic, Natasa; Slingsby, B. T.; Nissen, Steven E.; Beasley, Richard; Budoff, Matthew; Carr, George; Carroll, Michael; Cevallos Yepez, Jose; Chhabra, Anil; Cole, Frank; Dunn, Leonard; Eaves, William; Ebuh, Valentine; Estevez, Roger; Gould, Glenn; Hong, Matthew; Iteld, Bruce; Jain, Mahendra; Kemp, Charles; Kennelly, Christina; Kleiner, Mark; Kutner, Mark; Laffin, Luke; Lambert, Joseph; Ledesma, Gilbert; Lee, Keung; Lentz, John; Lupovitch, Steven; Luther, James; Lynn, Lon; Marquez, Obadias; Mazhar, Mobeen; Morin, David; Neutel, Joel; Oppong, Yaa; Osorio, Merlin; Patron, Andres; Pharr, Walter; Ponce de Leon, Mercedes; Rodriguez-Ables, Lilia; Rosen, Jeffrey; Sachmechi, Issac; Surowitz, Ronald; Wadsworth, Larkin; Wayne, Jeffrey; Zafar, Zahid (26 September 2023). "Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial". JAMA. 330 (12): 1140–1150. doi:10.1001/jama.2023.16029. ISSN 0098-7484. PMC 10493865. PMID 37690061.
  2. ^ Rodman, David; Weir, Matthew R.; Slingsby, Bt; Laffin, Luke; Nissen, Steven E. (March 2023). "Highly Effective Blood Pressure Lowering with MLS-101, A New Aldosterone Synthase Inhibitor, in Individuals with Obesity and Raas Dysregulation". Journal of the American College of Cardiology. 81 (8): 306. doi:10.1016/S0735-1097(23)00750-7. S2CID 257347846.
  3. ^ Fujii, Aya; Hiraga, Yuki; Kawai, Mizue; Ogawa, Kei; Ohta, Yoshiyasu; Rahman, Sheikh Mohammed Ashfaq; Shimizu, Hidetoshi; Sugimoto-Kawabata, Kanami; Van Iersel, Mattheus (Thijs); Van Lier, Jan Jaap; Slingsby, Bt; Rodman, David (March 2023). "First-In-Human Study of MLS-101, A Potent and Highly Selective Aldosterone Synthase Inhibitor". Journal of the American College of Cardiology. 81 (8): 616. doi:10.1016/S0735-1097(23)01060-4. S2CID 257350703.
  4. ^ Irfan, Hamza; Ahmed, Aliza; Nawani, Komal Devi (January 2024). "Hypertension and Lorundrostat: Key Discoveries From the TARGET-HTN Trial". Current Problems in Cardiology. 49 (1) 102144. doi:10.1016/j.cpcardiol.2023.102144. PMID 37858848. S2CID 264334619.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.